📋 Pep IQ provides independent reference information for educational purposes only. Nothing here constitutes medical advice or treatment recommendation. All compounds require individual assessment. Consult a qualified physician before considering any peptide protocol.
NAD+ Precursors Vitamin B3 Family

NAD+ / NMN / NR

Nicotinamide Adenine Dinucleotide · NMN · Nicotinamide Riboside · B3 Derivatives

"The molecule every cell in your body depends on — and the one that declines most reliably with age. NAD+ sits at the intersection of energy metabolism, DNA repair, sirtuin activation, and inflammation. Restoring it is one of the most mechanistically compelling longevity interventions available."

Type
Essential coenzyme · energy metabolism cofactor
Precursors
NMN · NR · Niacin · Nicotinamide
Status
UK: food supplement (NMN, NR) · widely sold · WADA: not specifically listed · US FDA: GRAS for NR, NMN regulatory status disputed 2022+
Routes
Oral · IV infusion · IM · Intranasal
Protocol summary
NMN oral dose
300–900 mg/day
Optimal in trials
600 mg/day
Form
Supplements (precursors)
Evidence-based
NMN 300–900 mg/day oral · 600 mg/day optimal for biomarker change · NR 300–1000 mg/day
Real but modest benefits — these are not the longevity miracle marketing claims suggest
How we read the evidence
NAD+ precursors with growing human RCT evidence · NMN doses up to 900 mg/day safe in trials · 600 mg optimal for biomarkers · benefits real but modest, not the longevity miracle marketing claims
Animal evidence

Substantial preclinical foundation. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to mitochondrial energy production, sirtuin activation, and DNA repair. NAD+ levels decline with age in skin, blood, liver, muscle, and brain. NMN (nicotinamide mononucleotide) is a direct NAD+ precursor that animal studies (Yoshino 2011, Mills 2016, others) showed restores NAD+ levels and improves multiple healthspan markers in mice — including improved insulin sensitivity, vascular function, neurogenesis, and exercise capacity. NR (nicotinamide riboside) follows the same pathway with similar but distinct PK.

Community & clinical practice

Community use is oral supplementation, not peptide injection — NMN and NR are small molecules taken as capsules or sublingual lozenges. Standard doses: 300–900 mg/day NMN, with 600 mg/day producing peak biomarker response in dose-finding trials. NR is dosed similarly (100–2000 mg/day across trials). Often combined with TMG (trimethylglycine) for methylation support, resveratrol or pterostilbene for sirtuin co-activation, and exercise (which itself raises NAD+ through NAMPT upregulation). IV NAD+ infusions exist at clinics but the peripheral-to-CNS bioavailability question is unresolved.

Human trial data

Substantial and growing. Yoshino et al. 2021 — RCT in obese postmenopausal women with prediabetes showed NMN improved muscle insulin sensitivity. Igarashi et al. 2022 (NPJ Aging) — chronic NMN supplementation in healthy older men elevated blood NAD+ and altered muscle function. Multicentre Phase trial NCT04823260 (Pubmed 36482258) — randomised, double-blind, placebo-controlled, dose-response in 80 healthy middle-aged adults across 300/600/900 mg NMN: safe and well-tolerated up to 900 mg, peak efficacy at 600 mg/day for blood NAD+ concentration and physical performance. NR trials at 100–2000 mg/day across 12+ studies show consistent safety and NAD+ elevation; recent work (NCT04228640 Uthever NMN trial) shows preserved HOMA-IR vs deterioration in placebo. Effect sizes are modest — meaningful biomarker changes, but not transformative healthspan gains in short-term trials.

Regulatory status

Not regulated as drugs — categorised as dietary supplements in most markets. NMN had a brief FDA reclassification controversy in 2022–2023 (drug development applications for separate NMN therapeutic complicated supplement status) but is currently sold as a supplement. NR is sold as a supplement under the brand Niagen (ChromaDex) and others. Quality varies dramatically between supplement brands — third-party testing matters more here than in pharmaceutical markets.

Convergence

NAD+ precursors are unusual on this platform: they're small-molecule supplements rather than peptides, but they share the longevity-medicine context and are commonly stacked with peptide protocols. The human evidence base is the strongest of any longevity-targeted intervention discussed here — multiple RCTs, dose-response data, consistent safety profile up to 900 mg/day NMN, peak efficacy at 600 mg/day. Effect sizes are modest but real (improved NAD+ levels, biomarker shifts, modest functional improvements in older adults). Pep IQ flags this honestly: NAD+ precursors work mechanistically and have the best human evidence base of any longevity supplement, but the marketing of dramatic anti-ageing effects significantly exceeds what trials have demonstrated. Useful as part of a broader healthspan strategy; not the singular intervention many vendors claim.

Origin & Background

The molecule at the centre of cellular energy

Nicotinamide adenine dinucleotide (NAD+) is one of the most fundamental molecules in biology. Every living cell uses it — as an electron carrier in energy metabolism (shuttling electrons in glycolysis and the TCA cycle to generate ATP), as a substrate for sirtuin enzymes (the "longevity proteins" that regulate gene expression, DNA repair, and stress responses), and as a substrate for PARP enzymes (which repair DNA damage). Without NAD+, cellular energy production stops entirely.

NAD+ levels decline reliably with age — estimated to fall by 50% between young adulthood and midlife in many tissues. This decline is now considered a potential primary driver of many hallmarks of ageing: mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and increased inflammation. Restoring NAD+ has become one of the most studied longevity interventions.

Direct NAD+ supplementation has poor oral bioavailability. The more effective approach is supplementing with precursors that the body converts into NAD+. The two most studied are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — both members of the vitamin B3 family, both available as supplements, and both with a growing human clinical trial base. The David Sinclair (Harvard) research programme brought these compounds to mainstream awareness from 2013 onward.

NMN vs NR vs Niacin: NMN is one step closer to NAD+ in the biosynthetic pathway and may have superior tissue uptake in some contexts. NR requires conversion to NMN before becoming NAD+. Both have shown NAD+ elevation in human trials. Niacin (nicotinic acid) is the cheapest precursor and also raises NAD+ but causes the well-known "niacin flush" (prostaglandin-mediated vasodilation). Nicotinamide (plain niacinamide) raises NAD+ but inhibits sirtuins at high doses — a significant concern. For longevity applications, NMN or NR are preferred.

Science & Mechanism

Sirtuin activation, DNA repair, and mitochondria

How NAD+ Precursors Work

1
Conversion to NAD+: NMN → NAD+ via NMNAT enzymes. NR → NMN → NAD+ via NRK kinases. Both raise intracellular and blood NAD+ levels consistently in human trials — confirmed in multiple RCTs from 2022 onward.
2
Sirtuin activation (SIRT1–7): Sirtuins are NAD+-dependent deacetylases that regulate gene expression, stress responses, mitochondrial biogenesis, and inflammation. They require NAD+ as a co-substrate — without sufficient NAD+, sirtuin activity falls. Restoring NAD+ reactivates sirtuin function.
3
PARP activation — DNA repair: PARP enzymes detect and repair DNA strand breaks, consuming NAD+ in the process. As DNA damage accumulates with age, PARP activity increases — competing with sirtuins for NAD+. NMN/NR supplementation provides NAD+ for both systems.
4
Mitochondrial biogenesis: Sirtuin 1 (SIRT1) activates PGC-1α — the master regulator of mitochondrial biogenesis. Raising NAD+ → activating SIRT1 → activating PGC-1α → more mitochondria → better energy production. This is the chain linking NAD+ to exercise performance and metabolic health.
5
Anti-inflammatory via NF-κB suppression: NAD+-fueled sirtuin activity suppresses NF-κB — the key inflammatory transcription factor. This reduces pro-inflammatory cytokines. NR supplementation in older humans has been shown to reduce inflammatory markers significantly.

Human clinical evidence has expanded substantially since 2021. The pivotal Yoshino et al. (2022) trial showed 250mg/day NMN for 10 weeks in overweight women with prediabetes significantly improved muscle insulin sensitivity by 25% — the gold-standard euglycaemic clamp measurement. NMN also raised NAD+ in muscle, reduced fat mass, and improved muscle gene expression. A 2023 RCT showed NMN supplementation significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. Multiple trials have confirmed oral NMN reliably raises blood NAD+ levels in humans.

A 2024 GeroScience RCT of NMN in older adults showed increased blood NAD+ levels, maintained walking speed, and improved sleep quality. The 2025 meta-analysis (Prokopidis et al., J Cachexia Sarcopenia Muscle) confirmed that NMN and NR supplementation improved skeletal muscle mass and function. The 2025 systems approach trial (Nature npj Aging) showed that targeting multiple NAD+ pathway points simultaneously produced greater NAD+ elevation than single-precursor supplementation, along with SIRT1 activation, reduced pro-inflammatory cytokines, and shifts toward younger biological age markers.

Benefits & Evidence

What the data shows

⚡
NAD+ elevation in blood and tissues
Multiple RCTs confirm oral NMN and NR reliably raise blood NAD+ levels in humans. Liposomal NMN shows superior elevation vs standard NMN in head-to-head trial (2025). This is the most consistently proven effect — the downstream health benefits are extrapolated from the NAD+ elevation.
● Strong — multiple RCTs
💪
Muscle insulin sensitivity and metabolic health
Yoshino (2022): 25% improvement in muscle insulin sensitivity vs placebo in premenopausal women with prediabetes. 2025 meta-analysis: NMN and NR improved skeletal muscle mass and function. 2023 RCT: reduced LDL, body weight, and diastolic blood pressure.
● Moderate — growing RCT base
🧠
Cognitive function and neurodegeneration
2024 RCT: NR in older adults with mild cognitive impairment — results variable but NR improved some cognitive markers. NAD+ depletion is strongly implicated in Alzheimer's disease models. Multiple trials in neurodegenerative disease underway. Emerging but not yet established in humans.
● Emerging — trials underway
🫀
Cardiovascular and vascular health
NMN reversed arterial endothelial dysfunction in old mice. 2023 human trial: reduced arterial stiffness. NR reduced inflammatory markers in older adults. The vascular evidence base in humans is growing but modest in scale.
● Moderate — small human trials
💤
Sleep quality and physical performance
2024 GeroScience RCT: NMN maintained walking speed and improved sleep quality in older adults. Resistance training raises muscle NAD+ and NAMPT — the lifestyle approach to NAD+ restoration with the strongest evidence base.
● Moderate — recent RCT
Things to know

Risks & considerations

🛡️
Well-tolerated across all completed human trials. NMN and NR are members of the B3 vitamin family. No serious adverse events have been reported across dozens of human trials. The safety profile is one of the strongest of any longevity supplement in this book — arguably second only to collagen peptides.
Mild
Mild GI discomfort — occasional nausea, bloating, or loose stools at higher doses. Usually resolves with splitting doses or taking with food.
Mild
Niacin flush (niacin only) — hot, red, itching skin due to prostaglandin-mediated vasodilation. Not seen with NMN or NR. Specific to nicotinic acid (niacin) form. Dose-dependent and tolerability improves with continued use.
Moderate
Nicotinamide (niacinamide) at high doses — sirtuin inhibition: Plain nicotinamide raises NAD+ but also inhibits sirtuin enzymes at high concentrations — the opposite of what's intended for longevity purposes. Avoid high-dose nicotinamide as the primary NAD+ strategy.
Unknown
Long-term effects uncertain: Most RCTs are 8–24 weeks. Long-term NAD+ elevation effects in humans are not characterised. NAD+ also feeds cancer cell energy metabolism — whether supplementation affects cancer risk is an active research question without a clear answer.
Fast Facts
What it isEssential coenzyme · all living cells
Best precursorsNMN · NR · both raise blood NAD+
Typical dose250–500mg NMN · 300–600mg NR/day
When to takeMorning · circadian alignment
Key mechanismSirtuin activation · PARP repair · mitochondria
FDA statusGRAS / supplement status
WADANot prohibited
Related Peptides
MOTS-cMitochondrial longevity overlap
SS-31Mitochondrial protection
EpitalonLongevity / anti-ageing overlap
AICARAMPK activator · NAD+ synergy